Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery
Name
Langer_Transepithelial.pdf
Size
996.09 KB
Format
Adobe PDF
Checksum (MD5)
61bef63a2486b9f0adb202d21577822e
Author(s)
Pridgen, Eric M.
Alexis, Frank
Kuo, Timothy T.
Levy-Nissenbaum, Etgar
Karnik, Rohit
Blumberg, Richard S.
Langer, Robert
Farokhzad, Omid C.
Date Issued
November 2013
Journal
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Citation
Pridgen, E. M., F. Alexis, T. T. Kuo, E. Levy-Nissenbaum, R. Karnik, R. S. Blumberg, R. Langer, and O. C. Farokhzad. “Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery.” Science Translational Medicine 5, no. 213 (November 27, 2013): 213ra167–213ra167.
Version
Author's final manuscript
Abstract
Nanoparticles are poised to have a tremendous impact on the treatment of many diseases, but their broad application is limited because currently they can only be administered by parenteral methods. Oral administration of nanoparticles is preferred but remains a challenge because transport across the intestinal epithelium is limited. We show that nanoparticles targeted to the neonatal Fc receptor (FcRn), which mediates the transport of immunoglobulin G antibodies across epithelial barriers, are efficiently transported across the intestinal epithelium using both in vitro and in vivo models. In mice, orally administered FcRn-targeted nanoparticles crossed the intestinal epithelium and reached systemic circulation with a mean absorption efficiency of 13.7%*hour compared with only 1.2%*hour for nontargeted nanoparticles. In addition, targeted nanoparticles containing insulin as a model nanoparticle-based therapy for diabetes were orally administered at a clinically relevant insulin dose of 1.1 U/kg and elicited a prolonged hypoglycemic response in wild-type mice. This effect was abolished in FcRn knockout mice, indicating that the enhanced nanoparticle transport was specifically due to FcRn. FcRn-targeted nanoparticles may have a major impact on the treatment of many diseases by enabling drugs currently limited by low bioavailability to be efficiently delivered though oral administration.
MIT Department
MIT-Harvard Center for Cancer Nanotechnology Excellence
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1126/scitranslmed.3007049
